Table 1.

New anti-HER2 agents

General strategy	Identification	Target	Reference
Inhibiting downstream signaling pathways of HER2	Perifosine	PI3-kinase/Akt	108
	Everolimus	mTor	109
	GDC-0941	PI3K	43
HER family TK inhibitors	Lapatinib	Dual TK inhibitor of EGFR and HER2 approved for clinical use	110, 111
	Neratinib (HKI-272)	TK inhibitor: HER1/HER2	110
	BIBW2992	Irreversible dual HER1/HER2 inhibitor	112
Inhibiting the activity of other growth factor receptors	Pertuzumab	HER2/HER3	41
	rhIGFBP-3	IGF-1R	113
	IMC-A12	IGF-1R	114
	BMS-554417	IGF-1R	115
	SU11274	MET	100
Decreasing the expression of protein processing of HER2 and other signaling components	Tanespimycin (17-AAG)	HSP90 inhibitor	116
	LAQ824	Histone deacetylase (HDAC) inhibitors	117
	Bortezomib	Proteasome inhibitor	118
Increasing toxicity of trastuzumab to HER2 positive cells	Trastuzumab-DM1 immunotoxin	HER2	119
Increasing immunity against HER2 positive cells	HER2 vaccines	Anti-HER2 vaccine	120
	Ertumaxomab	Trifunctional bispecific antibody targeting HER2 and CD3	121
	Genetically engineered Fc of mAb	Enhanced FcγRIII receptor binding on effector cells	104